Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136,795 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.
Han B, Song Y, Li C, Yang W, Ma Q, Jiang Z, Li M, Lian X, Jiao W, Wang L, Shu Q, Wu Z, Zhao Y, Li Q, Gao Q. Han B, et al. Among authors: wang l. Lancet Infect Dis. 2021 Dec;21(12):1645-1653. doi: 10.1016/S1473-3099(21)00319-4. Epub 2021 Jun 28. Lancet Infect Dis. 2021. PMID: 34197764 Free PMC article. Clinical Trial.
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, Li M, Jin H, Cui G, Chen P, Wang L, Zhao G, Ding Y, Zhao Y, Yin W. Wu Z, et al. Among authors: wang l. Lancet Infect Dis. 2021 Jun;21(6):803-812. doi: 10.1016/S1473-3099(20)30987-7. Epub 2021 Feb 3. Lancet Infect Dis. 2021. PMID: 33548194 Free PMC article. Clinical Trial.
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.
Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, Wu Z, Jiang D, Deng X, Chu K, Zheng W, Wang L, Lu W, Han B, Zhao Y, Zhu F, Yu H, Yin W. Zeng G, et al. Among authors: wang l. Lancet Infect Dis. 2022 Apr;22(4):483-495. doi: 10.1016/S1473-3099(21)00681-2. Epub 2021 Dec 8. Lancet Infect Dis. 2022. PMID: 34890537 Free PMC article. Clinical Trial.
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, Jia SY, Jiang HD, Wang L, Jiang T, Hu Y, Gou JB, Xu SB, Xu JJ, Wang XW, Wang W, Chen W. Zhu FC, et al. Among authors: wang w, wang l, wang xw, wang z, wang bs, wang wj. Lancet. 2020 Jun 13;395(10240):1845-1854. doi: 10.1016/S0140-6736(20)31208-3. Epub 2020 May 22. Lancet. 2020. PMID: 32450106 Free PMC article. Clinical Trial.
Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study.
Wang X, Deng Y, Zhao L, Wang L, Fu Z, Tang L, Ye F, Liu Q, Wang W, Wang S, Hu B, Guan X, Han Z, Tong Y, Rodewald LE, Yin Z, Tan W, Wang F, Huang B. Wang X, et al. Among authors: wang w, wang f, wang l, wang s. Vaccine. 2022 Sep 16;40(39):5701-5708. doi: 10.1016/j.vaccine.2022.08.037. Epub 2022 Aug 22. Vaccine. 2022. PMID: 36031501 Free PMC article.
Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants.
Wang K, Jia Z, Bao L, Wang L, Cao L, Chi H, Hu Y, Li Q, Zhou Y, Jiang Y, Zhu Q, Deng Y, Liu P, Wang N, Wang L, Liu M, Li Y, Zhu B, Fan K, Fu W, Yang P, Pei X, Cui Z, Qin L, Ge P, Wu J, Liu S, Chen Y, Huang W, Wang Q, Qin CF, Wang Y, Qin C, Wang X. Wang K, et al. Among authors: wang x, wang l, wang y, wang n, wang q. Nature. 2022 Mar;603(7903):919-925. doi: 10.1038/s41586-022-04466-x. Epub 2022 Jan 28. Nature. 2022. PMID: 35090164 Free PMC article.
A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2.
Zhang L, Cao L, Gao XS, Zheng BY, Deng YQ, Li JX, Feng R, Bian Q, Guo XL, Wang N, Qiu HY, Wang L, Cui Z, Ye Q, Chen G, Lu KK, Chen Y, Chen YT, Pan HX, Yu J, Yao W, Zhu BL, Chen J, Liu Y, Qin CF, Wang X, Zhu FC. Zhang L, et al. Among authors: wang x, wang l, wang n. Natl Sci Rev. 2021 Mar 27;8(8):nwab053. doi: 10.1093/nsr/nwab053. eCollection 2021 Aug. Natl Sci Rev. 2021. PMID: 34676098 Free PMC article.
Selection and structural bases of potent broadly neutralizing antibodies from 3-dose vaccinees that are highly effective against diverse SARS-CoV-2 variants, including Omicron sublineages.
Wang L, Fu W, Bao L, Jia Z, Zhang Y, Zhou Y, Wu W, Wu J, Zhang Q, Gao Y, Wang K, Wang Q, Qin C, Wang X. Wang L, et al. Among authors: wang x, wang k, wang q. Cell Res. 2022 Jul;32(7):691-694. doi: 10.1038/s41422-022-00677-z. Epub 2022 Jun 7. Cell Res. 2022. PMID: 35672388 Free PMC article. No abstract available.
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L, Du S, Wang J, Li Q, Chen X, Yu Y, Wang P, Zhang Z, Liu P, An R, Hao X, Wang Y, Wang J, Feng R, Sun H, Zhao L, Zhang W, Zhao D, Zheng J, Yu L, Li C, Zhang N, Wang R, Niu X, Yang S, Song X, Chai Y, Hu Y, Shi Y, Zheng L, Li Z, Gu Q, Shao F, Huang W, Jin R, Shen Z, Wang Y, Wang X, Xiao J, Xie XS. Cao Y, et al. Among authors: wang x, wang l, wang j, wang y, wang p, wang r. Nature. 2022 Aug;608(7923):593-602. doi: 10.1038/s41586-022-04980-y. Epub 2022 Jun 17. Nature. 2022. PMID: 35714668 Free PMC article.
136,795 results
You have reached the last available page of results. Please see the User Guide for more information.